Brainsway Ltd. Sponsored ADR (NASDAQ:BWAY) Short Interest Up 191.8% in August

Brainsway Ltd. Sponsored ADR (NASDAQ:BWAY) was the target of a large growth in short interest during the month of August. As of August 31st, there was short interest totaling 191,700 shares, a growth of 191.8% from the August 15th total of 65,700 shares. Currently, 1.3% of the shares of the company are sold short. Based on an average daily trading volume, of 64,200 shares, the short-interest ratio is currently 3.0 days. Based on an average daily trading volume, of 64,200 shares, the short-interest ratio is currently 3.0 days. Currently, 1.3% of the shares of the company are sold short.

Institutional Trading of Brainsway

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Valor Management LLC purchased a new stake in Brainsway in the fourth quarter valued at approximately $19,838,000. ARK Investment Management LLC raised its position in Brainsway by 6.1% in the second quarter. ARK Investment Management LLC now owns 199,826 shares of the company’s stock valued at $2,628,000 after purchasing an additional 11,498 shares during the period. Two Sigma Investments LP raised its position in Brainsway by 2.0% in the fourth quarter. Two Sigma Investments LP now owns 92,755 shares of the company’s stock valued at $875,000 after purchasing an additional 1,786 shares during the period. Huntleigh Advisors Inc. raised its position in Brainsway by 5.7% in the second quarter. Huntleigh Advisors Inc. now owns 77,416 shares of the company’s stock valued at $1,018,000 after purchasing an additional 4,143 shares during the period. Finally, Eagle Global Advisors LLC purchased a new stake in Brainsway in the first quarter valued at approximately $590,000. Hedge funds and other institutional investors own 30.11% of the company’s stock.

Brainsway Stock Performance

BWAY stock opened at $15.77 on Friday. The firm has a market cap of $298.08 million, a PE ratio of 60.66 and a beta of 1.34. The firm’s 50 day moving average price is $13.48 and its 200-day moving average price is $11.19. Brainsway has a one year low of $7.84 and a one year high of $16.25.

Brainsway (NASDAQ:BWAY) last announced its earnings results on Wednesday, August 13th. The company reported $0.10 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.07 by $0.03. The company had revenue of $12.63 million for the quarter, compared to analyst estimates of $12.34 million. Brainsway had a return on equity of 8.97% and a net margin of 11.60%. Brainsway has set its FY 2025 guidance at EPS. Equities research analysts predict that Brainsway will post 0.08 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on the company. Northland Securities lifted their price objective on Brainsway from $15.00 to $19.00 and gave the company an “outperform” rating in a research note on Thursday, August 14th. Wall Street Zen upgraded Brainsway from a “hold” rating to a “buy” rating in a report on Sunday, August 17th. Finally, HC Wainwright reiterated a “buy” rating and issued a $17.00 price objective on shares of Brainsway in a report on Monday, August 25th. Two research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, Brainsway currently has an average rating of “Buy” and a consensus price target of $18.00.

Brainsway Company Profile

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.